このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cytokinetics マネジメント

マネジメント基準チェック /34

Cytokinetics'の CEO はRobert Blumで、 Feb2006年に任命され、の在任期間は 18.5年です。の年間総報酬は$ 8.75Mで、 9%給与と91%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.23%を直接所有しており、その価値は$ 15.57M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と13.8年です。

主要情報

Robert Blum

最高経営責任者

US$8.8m

報酬総額

CEO給与比率	9.0%
CEO在任期間	18.6yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3.4yrs
取締役会の平均在任期間	13.8yrs

経営陣の近況

Recent updates

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued

Oct 05

CEO報酬分析

Cytokinetics の収益と比較して、Robert Blum の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$545m
Mar 31 2024	n/a	n/a	-US$531m
Dec 31 2023	US$9m	US$790k	-US$526m
Sep 30 2023	n/a	n/a	-US$527m
Jun 30 2023	n/a	n/a	-US$540m
Mar 31 2023	n/a	n/a	-US$431m
Dec 31 2022	US$9m	US$742k	-US$389m
Sep 30 2022	n/a	n/a	-US$282m
Jun 30 2022	n/a	n/a	-US$216m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$6m	US$709k	-US$215m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$156m
Mar 31 2021	n/a	n/a	-US$135m
Dec 31 2020	US$5m	US$682k	-US$127m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$140m
Mar 31 2020	n/a	n/a	-US$132m
Dec 31 2019	US$3m	US$656k	-US$122m
Sep 30 2019	n/a	n/a	-US$118m
Jun 30 2019	n/a	n/a	-US$110m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$3m	US$630k	-US$106m
Sep 30 2018	n/a	n/a	-US$120m
Jun 30 2018	n/a	n/a	-US$131m
Mar 31 2018	n/a	n/a	-US$132m
Dec 31 2017	US$3m	US$612k	-US$128m

報酬と市場: Robertの総報酬 ($USD 8.75M ) は、 US市場 ($USD 8.39M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Robertの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Robert Blum (60 yo)

18.6yrs

在職期間

US$8,751,057

報酬

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Blum	CEO, President & Director	18.6yrs	US$8.75m	0.23% $ 14.3m
Robert Wong	VP & Chief Accounting Officer	5.3yrs	US$1.04m	0.0063% $ 391.1k
Fady Malik	Executive Vice President of Research & Development	12.3yrs	US$4.44m	0.059% $ 3.6m
Andrew Callos	Executive VP & Chief Commercial Officer	3.5yrs	US$3.20m	0.021% $ 1.3m
James Spudich	Co-Founder & Member of Scientific Advisory Board	27.1yrs	US$21.94k	データなし
Sung Lee	Executive VP & CFO	less than a year	データなし	データなし
Jeff Lotz	Vice President of Sales & Operations	3yrs	データなし	データなし
Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	less than a year	データなし	データなし
Steven Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	no data	データなし	データなし
Kari Loeser	VP & Chief Compliance Officer	2.8yrs	データなし	データなし
John Faurescu	VP, Associate General Counsel & Corporate Secretary	no data	データなし	データなし
Scott Jordan	Senior Vice President of Global Marketing & Commercial Strategy	3.3yrs	データなし	データなし

3.4yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: CYTKの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Blum	CEO, President & Director	17.7yrs	US$8.75m	0.23% $ 14.3m
James Spudich	Co-Founder & Member of Scientific Advisory Board	no data	US$21.94k	データなし
B. Parshall	Independent Director	11.6yrs	US$529.02k	0.013% $ 785.2k
Santo Costa	Independent Director	13.8yrs	US$524.02k	0.013% $ 785.2k
James H. Sabry	Co-Founder & Chairman of Scientific Advisory Board	16.4yrs	US$41.50k	データなし
Nancy Wysenski	Independent Director	3.8yrs	US$519.02k	0.015% $ 904.0k
John Henderson	Independent Chairman	15.6yrs	US$559.02k	0.028% $ 1.7m
John Lowe	Member of Scientific Advisory Board	no data	データなし	データなし
Thomas Pollard	Member of Scientific Advisory Board	no data	データなし	データなし
David Morgans	Member of Scientific Advisory Board	8.2yrs	US$942.23k	データなし
Lawrence S. Goldstein	Member of Scientific Advisory Board	no data	データなし	データなし
John Solaro	Member of Scientific Advisory Board	no data	データなし	データなし

13.8yrs

平均在職期間

70.5yo

平均年齢

経験豊富なボード: CYTKの取締役会は経験豊富で経験豊富です ( 13.8年の平均在任期間)。

Cytokinetics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director recently sold US$622k worth of stock

CEO, President & Director recently sold US$1.2m worth of stock

CEO, President & Director notifies of intention to sell stock

Recent updates

Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions

Consensus revenue estimates decrease by 23%

Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 54%

CEO, President & Director notifies of intention to sell stock

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

CEO, President & Director recently sold US$622k worth of stock

Consensus revenue estimates increase by 10%

CEO, President & Director recently sold US$1.2m worth of stock

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

CEO, President & Director notifies of intention to sell stock

VP & Chief Accounting Officer recently sold US$636k worth of stock

New minor risk - Insider selling

Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

Price target decreased by 7.5% to US$86.06

Consensus revenue estimates increase by 41%

Cytokinetics Decides To Go It Alone

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.

Consensus revenue estimates decrease by 13%

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

Insider notifies of intention to sell stock

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment

Consensus revenue estimates decrease by 12%

Independent Chairman notifies of intention to sell stock

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Insider exercised options and sold US$1.9m worth of stock

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated: Buyout Speculation Persists

Cytokinetics: CEO Talks Down Buyout Prospects

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 49%, EPS upgraded

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Pursuit of Cytokinetics Reportedly Cools

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

New major risk - Revenue and earnings growth

Price target increased by 20% to US$74.39

CEO, President & Director notifies of intention to sell stock

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Now 23% undervalued after recent price drop

CEO, President & Director exercised options and sold US$329k worth of stock

Insufficient new directors

CEO, President & Director notifies of intention to sell stock

Now 22% undervalued

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO, President & Director exercised options and sold US$319k worth of stock

Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023

Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

マネジメント基準チェック /34